Syntrix Pharmaceuticals today announced that it has dosed the first patient in its Phase 1/2 clinical trial that will combine SX-682 with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy. SX-682 is an oral dual inhibitor of CXCR1 and CXCR2 (CXCR1/2) being...
High Point Clinical Trials Center announced a 3-year collaboration with ProSciento to join NASH PASS as a site partner, according to a press release. NASH PASS is Prosciento’s program designed to combine select qualified sites and a proprietary methodology to improve...
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced results from an ongoing Phase 1b...
– Commenced patient enrollment in Phase 2 clinical trial of vopratelimab in combination with ipilimumab – – Preliminary efficacy and relationship to biomarker data expected in 2020 – CAMBRIDGE, Mass., June 18, 2019 (GLOBE NEWSWIRE) —...
– Phase IIIb study met all primary and secondary endpoints with statistical significance and demonstrated that linaclotide improved the overall abdominal symptoms of bloating, pain and discomfort in adults with IBS-C – – Results further support the efficacy and safety...
Email
Text